Audrey Weissman, MD
Allergy · Elmhurst, NYNPI 1780670919
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Optinose US, Inc. at 39.9% of the total. Reporting peaked in 2019 at $19,727 and has fallen 89.2% since, to $2,121 in 2025.
Across 573 payments — averaging $62.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$14K
- Pfizer$12K
- GSK$2K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$1K
- AstraZeneca$1K
- plus $4K from 35 others
What the payments were for
- Consulting fees$2,0006%
- Speaking & faculty fees$18,81553%
- Travel & lodging$2,9778%
- Food & beverage$11,34732%
- Education$6112%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,751 in reported general payments places this provider in the 85th percentile of 92 allergy providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 40 | $145,815 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 113 | $79,785 |
| XolairOmalizumab | 15 | $50,230 |
| Diclofenac Sodium | 54 | $45,448 |
| NucalaMepolizumab | 11 | $44,161 |
| ZenpepLipase/Protease/Amylase | 12 | $32,113 |
| ProliaDenosumab | 19 | $30,688 |
| Tacrolimus | 92 | $29,945 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $26,047 |
| Spiriva RespimatTiotropium Bromide | 32 | $25,118 |
| Epinephrine | 84 | $23,888 |
| EucrisaCrisaborole | 23 | $23,260 |
| EliquisApixaban | 30 | $20,263 |
| AirsupraAlbuterol Sulfate/Budesonide | 41 | $17,968 |
| RyaltrisOlopatadine Hcl/Mometasone | 72 | $17,146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta | $1,943 | $137,859154 claims |
| AstraZenecaBreztri Aerosphere, Airsupra | $1,123 | $44,01582 claims |
| PfizerEucrisa, Eliquis | $11,529 | $43,52453 claims |
| Hikma Pharmaceuticals USAEpinephrine, Ryaltris | $68 | $41,035156 claims |
| AmgenProlia | $528 | $30,68819 claims |
| Boehringer IngelheimSpiriva Respimat | $357 | $25,11832 claims |
| AbbVieLinzess | $295 | $15,82631 claims |
| MerckJanuvia | $23 | $15,65724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 92 allergy providers in New York.
Other allergy in Elmhurst
- Vahid RahimianElmhurst$28K
- Juan Abel Romero LoorElmhurst$3K
- Marc BraunsteinHewlett$884K
- Allison RamseyRochester$643K
- Christopher SmithHorseheads$622K
- Anne MaitlandTarrytown$292K
- Yudhistira PersaudBronx$127K
- Michael KatlanAlbany$91K
- Michel AklJamestown$90K
- Juan SotomayorNorth Syracuse$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.